Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Janux Therapeutics, Inc. Transaction History
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.
- $721 Billion
- Q3 2024
A detailed history of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. holds 471,736 shares of JANX stock, worth $26 Million. This represents 2.97% of its overall portfolio holdings.
Number of Shares
471,736Holding current value
$26 Million% of portfolio
2.97%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
166Shares Held
37.6MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$506 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$139 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$132 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$129 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$114 Million0.17% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.3B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...